A case analysis of multiple immune-related adverse event induced by toripalimab
- VernacularTitle:特瑞普利单抗致多种免疫相关性不良事件1例
- Author:
Zhen FENG
1
;
Yuzhen ZHANG
2
;
Cheng XIE
3
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China;Dept. of Pharmacy，the Affiliated Hospital of Xuzhou Medical University，Jiangsu Xuzhou 221006，China
2. Dept. of Cardiology，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China
3. Dept. of Pharmacy，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China
- Publication Type:Journal Article
- Keywords:
toripalimab;
immune-related adverse event;
myocarditis;
liver injury;
myasthenia;
adverse drug reaction
- From:
China Pharmacy
2025;36(1):96-100
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To explore the clinical features， diagnosis， treatment and management measures of multiple immune- related adverse event （irAE） after toripalimab treatment， in order to provide reference for the clinical management of similar cases. METHODS A retrospective analysis was conducted on a post-operative bladder cancer patient who developed various irAEs after toripalimab treatment. The patient’s medical history， laboratory tests， imaging studies， treatment course and outcomes were detailed. The Naranjo scale was used to assess the relationship between the irAEs and toripalimab. RESULTS The patient developed irAEs after receiving toripalimab， such as immune-related myocarditis， liver dysfunction， and myasthenia. According to the Naranjo scale evaluation， it was assessed that these adverse events were related to the administration of toripalimab. After high- dose corticosteroid pulse therapy and immunoglobulin immunomodulation， the patient’s symptoms were effectively relieved， with a improved trend in various physiological indicators and significant improvement in the degree of system/organ damage. CONCLUSIONS Toripalimab may lead to multiple irAEs， including immune-related myocarditis， liver injury， and myasthenia. Early recognition， timely diagnosis， and appropriate treatment of irAE are crucial for improving patient’s prognosis.
